静脉血栓栓塞症治疗的新型抗血栓策略
静脉血栓栓塞症(VTE)抗凝治疗后仍有高达50%的深静脉血栓患者发生血栓后综合征、高达4%的肺栓塞患者发生慢性血栓栓塞性肺动脉高压,且出血副作用突出。本文围绕因子XII和XI抑制剂、增强内源性纤溶及抑制炎症等新型策略,阐述更安全抗血栓治疗的必要性、依据、在研药物数据与临床应用前景。
要点
- VTE抗凝后仍存在血栓后综合征和慢性血栓栓塞性肺动脉高压风险。
- 因子XII和XI是开发更安全抗凝药物的新靶点。
- 增强纤溶和抑制炎症分别针对肺栓塞和深静脉血栓并发症。
核心结论
- 需要更安全的抗血栓治疗以降低VTE并发症和出血风险。
- 因子XII和XI抑制剂是有前景的更安全抗凝策略。
- 增强内源性纤溶和阻断白细胞与血管壁相互作用是减少VTE并发症的新方向。
主要发现
- 高达50%的深静脉血栓患者发生血栓后综合征。
- 高达4%的肺栓塞患者发生慢性血栓栓塞性肺动脉高压。
- 直接口服抗凝药较华法林更方便安全,但出血仍是主要副作用,尤其在癌症患者中。
临床怎么用
- 关注因子XII和XI抑制剂等更安全抗凝药物的研发进展。
- 肺栓塞患者可考虑增强内源性纤溶的治疗策略。
- 深静脉血栓患者可考虑抑制炎症以降低血栓后综合征风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause of vascular death after heart attack and stroke. Anticoagulation therapy is the cornerstone of VTE treatment. Despite such therapy, up to 50% of patients with DVT develop postthrombotic syndrome, and up to 4% of patients with PE develop chronic thromboembolic pulmonary hypertension. Therefore, better therapies are needed. Although direct oral anticoagulants are more convenient and safer than warfarin for VTE treatment, bleeding remains the major side effect, particularly in cancer patients. Factor XII and factor XI have emerged as targets for new anticoagulants that may be safer. To reduce the complications of VTE, attenuation of thrombin activatable fibrinolysis inhibitor activity is under investigation in PE patients to enhance endogenous fibrinolysis, whereas blockade of leukocyte interaction with the vessel wall is being studied to reduce the inflammation that contributes to postthrombotic syndrome in DVT patients. Focusing on these novel antithrombotic strategies, this article explains why safer anticoagulants are needed, provides the rationale for factor XII and XI as targets for such agents, reviews the data on the factor XII- and factor XI-directed anticoagulants under development, describes novel therapies to enhance fibrinolysis and decrease inflammation in PE and DVT patients, respectively, and offers insights into the opportunities for these novel VTE therapies.
引用
- Weitz JI, Chan NC. Novel antithrombotic strategies for treatment of venous thromboembolism. Blood. 2020. PMID: 31917385. doi:10.1182/blood.2019000919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。